about
Digoxin use and risk of invasive breast cancer: evidence from the Nurses' Health Study and meta-analysis.Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifenImpact of acquired comorbidities on all-cause mortality rates among older breast cancer survivorsStatins and breast cancer prognosis: evidence and opportunities.Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue.CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors.Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study.Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer studyThe association between vitamin K antagonist therapy and site-specific cancer incidence estimated by using heart valve replacement as an instrumental variable.Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study.Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control studyNo increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medicationsCYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset.Family History of Breast Cancer, Breast Density, and Breast Cancer Risk in a U.S. Breast Cancer Screening Population.Population Exposure to Phthalate-containing Drugs.Associations of Statin Use With Colorectal Cancer Recurrence and Mortality in a Danish Cohort.Continuous measurement of breast tumour hormone receptor expression: a comparison of two computational pathology platforms.Comment on 'Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy'.Lifetime tobacco smoke exposure and breast cancer incidence.Modification of tamoxifen response: what have we learned?Development of a predictive miRNA signature for breast cancer risk among high-risk women.Association between use of phthalate-containing medication and semen quality among men in couples referred for assisted reproduction.Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study.Trends in breast-conserving surgery in Denmark, 1982-2002.Statins: a role in breast cancer therapy?Expression of survivin does not appear to influence breast cancer recurrence riskAssociation of Statin Use With Overall and Cancer SurvivalCumulative exposure to phthalates from phthalate-containing drug products: a Danish population-wide studyTowards a more precise and individualized assessment of breast cancer riskUse of antipsychotics and risk of breast cancer: a Danish nationwide case-control study.Bias analysis to guide new data collectionRe: Use of archived specimens in evaluation of prognostic and predictive biomarkersPost-Discharge Opioid Prescribing and Use after Common Surgical ProcedureRe: Beta Blockers and Improved Progression-Free Survival in Patients With Advanced HER2 Negative Breast CancerPharmacoepidemiology in PharmacogeneticsImproving the transparency of meta-analyses with interactive web applicationsCirculating lipids, mammographic density, and risk of breast cancer in the Nurses' Health Study and Nurses' Health Study IIExposure to phthalate-containing prescription drugs and the risk of colorectal adenocarcinoma: A Danish nationwide case-control study
P50
Q33566322-824EA37B-A267-4947-9CDB-8F97571AF026Q33940729-F73B3E6F-5B73-4775-8FCF-5B047A85B396Q34104905-30397821-76ED-4CBD-BC28-B4C684B3F933Q34206487-21CC260A-3FCB-4E42-AE27-80BC8B54766BQ34389561-B776403A-1865-4E6D-B7CB-6D0D7EC1001AQ34677193-DC7557D7-91B5-4AC9-B594-50076989B6A7Q35204531-9483A25C-E5F3-41E0-82B8-B45CE9166EDDQ35268601-9A3D936A-EBFE-4FAC-BD63-2E9E255634EDQ35690804-0F48415E-D3C0-40CA-B8EE-92F7900749A1Q35747189-1B2C5A80-60E1-454D-BEB8-807D6B4DC754Q36858268-AD1E2C2B-447F-4A9A-8F61-99B9E1F378FAQ36916770-9D89BD9E-DA98-4950-BB88-E0256E614D6AQ37131343-81192E30-7956-4BB1-895C-12A505FDD48DQ37343277-D290B9AD-EDC8-4577-B1C4-DF343ECB8441Q38629670-C0EF34BB-0DDE-449D-8E16-C6ED8A90515FQ38769347-D40CC01F-A6A7-4327-8875-F2B8F3291AC9Q38858862-C9A89172-E644-48C8-862C-3F38CF396636Q38879558-A90D08C3-D380-4127-A83D-5AFC6695DA06Q39301594-F777C753-C861-47CD-B3C2-804C2D264838Q42581544-30343CAC-D40E-4DDD-AF1D-AA8033611ADFQ44854411-C8A52087-A8DD-4113-A191-E069ACFF3353Q46674502-CD19FEB5-4926-4F72-8536-3FA6831375F3Q47724615-9DCC1E9F-62F3-4E1F-BB1E-1B2C50BAADCAQ48501060-DC6C1F7A-56D4-48AD-B904-C522645AF5E3Q48669007-75C1E5FC-5678-4D67-8B1C-9D42135D5B82Q50546357-5F007E3F-1FC6-459C-9F6A-4DC2C13A199CQ57105348-F0A1025B-C77D-4E00-AC0B-3E843FC26EC5Q57795219-1AD25F5B-A775-45B7-A1C9-A13480FB35E6Q59441437-1503F8F6-D60C-4951-BE53-BE6F46C2298DQ60589843-24F31829-0B44-4EF6-8147-76891F88E11BQ64240122-1B6BA0C0-C832-492F-B078-83C7EDE24CDCQ64965097-7D9D76D5-860D-45EE-986D-A7A18F1E942BQ83880589-12E2CFA0-90AD-4718-96FB-F182573B205EQ84943871-51A09079-2099-487F-9C96-3627130B5B6AQ87939510-4ADAE0E1-D815-4943-8395-6AA24AA27777Q88714879-0A824785-962D-4D7D-8CBF-D89734793456Q88818022-F9695D00-2940-4084-917D-B9799A401D98Q90710672-84D40D4E-B91D-4DE6-AC61-8560DF70A290Q91538579-26DBF153-C983-4852-A4CC-DA53622C104AQ91826011-F7EFD30C-8057-4ABD-96DC-BB622C16B689
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Thomas P Ahern
@ast
Thomas P Ahern
@en
Thomas P Ahern
@es
Thomas P Ahern
@nl
Thomas P Ahern
@sl
type
label
Thomas P Ahern
@ast
Thomas P Ahern
@en
Thomas P Ahern
@es
Thomas P Ahern
@nl
Thomas P Ahern
@sl
prefLabel
Thomas P Ahern
@ast
Thomas P Ahern
@en
Thomas P Ahern
@es
Thomas P Ahern
@nl
Thomas P Ahern
@sl
P106
P21
P31
P496
0000-0003-0440-8727